Effects of cardiac medications for patients with obstructive coronary artery disease by coronary computed tomographic angiography : results from the multicenter CONFIRM registry by J. Schulman-Marcus et al.
Effects of Cardiac Medications for Patients With Obstructive 
Coronary Artery Disease by Coronary Computed Tomographic 
Angiography: Results from the Multicenter CONFIRM Registry
Joshua Schulman-Marcus, MDa, Bríain ó Hartaigh, PhDb, Ashley E Giambrone, PhDc, Heidi 
Gransar, MSd, Valentina Valenti, MDb, Daniel S. Berman, MDd, Matthew J. Budoff, MDe, 
Stephan Achenbach, MDf, Mouaz Al-Mallah, MDg, Daniele Andreini, MDh, Filippo 
Cademartiri, MD, PhDi, Tracy Q. Callister, MDj, Hyuk-Jae Chang, MDk, Kavitha Chinnaiyan, 
MDl, Benjamin J. W. Chow, MDm, Ricardo Cury, MDn, Augustin Delago, MDo, Martin 
Hadamitzky, MDp, Joerg Hausleiter, MDq, Gudrun Feuchtner, MDr, Yong-Jin Kim, MDs, 
Philipp A. Kaufmann, MDt, Jonathon Leipsic, MDu, Fay Y. Lin, MDa, Erica Maffei, MDv, 
Gianluca Pontone, MDh, Gilbert Raff, MDl, Leslee J. Shaw, PhDw, Todd C. Villines, MDx, 
Allison Dunning, MSy, and James K Min, MDb
a
 Department of Medicine, The NewYork-Presbyterian Hospital and the Weill Cornell Medical 
College, New York, NY b Department of Radiology, The NewYork-Presbyterian Hospital and the 
Weill Cornell Medical College, New York, NY c Department of Healthcare Policy and Research, 
Weill Cornell Medical College, New York, NY d Department of Imaging and Division of Cardiology, 
Department of Medicine, Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, 
CA e Department of Medicine, Harbor UCLA Medical Center, Los Angeles, California f 
Department of Medicine, University of Erlangen, Erlangen, Germany g Department of Medicine, 
Wayne State University, Henry Ford Hospital, Detroit, Michigan h Department of Clinical Sciences 
and Community Health, University of Milan, Centro Cardiologico Monzino, IRCCS Milan, Italy i 
Cardio Vascular Imaging Unit, Giovanni XXIII Hospital, Monastier, Italy and Department of 
Radiology, Erasmus Medical Center, Rotterdam, The Netherlands j Tennessee Heart and 
Vascular Institute, Hendersonville, Tennessee, USA k Division of Cardiology, Severance 
Cardiovascular Hospital, Seoul, South Korea l William Beaumont Hospital, Royal Oaks, Michigan 
m
 Department of Medicine and Radiology, University of Ottawa Heart Institute, Ontario, Canada n 
Baptist Cardiac and Vascular Institute, Miami, FL, USA o Capitol Cardiology Associates, Albany, 
New York, USA p Division of Cardiology, DeutschesHerzzentrumMünchen, Munich, Germany q 
Medizinische Klinik I der Ludwig-Maximilians-Universität München, Munich, Germany r 
Department of Radiology, Medical University of Innsbruck, Innsbruck, Austria s Department of 
Medicine and Radiology, Seoul National University Hospital, Seoul, South Korea t Department of 
© 2014 Elsevier Ltd. All rights reserved.
Address for correspondence: James K. Min, MD, FACC, FSCCT, 413 East 69th Street, Suite 108, Dalio Institute of Cardiovascular 
Imaging, Weill Cornell Medical College and the NewYork-Presbyterian Hospital, New York, NY 10021, Phone: 646-962-6268, 
jkm2001@med.cornell.edu. 
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Atherosclerosis. Author manuscript; available in PMC 2016 January 01.
Published in final edited form as:
Atherosclerosis. 2015 January ; 238(1): 119–125. doi:10.1016/j.atherosclerosis.2014.11.007.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Nuclear Cardiology, Cardiovascular Center, University Hospital Zurich, Zurich, Switzerland u 
Department of Medical Imaging and Division of Cardiology, St. Paul's Hospital, University of 
British Columbia, Vancouver, BC v Cardio Vascular Imaging Unit, Giovanni XXIII Hospital, 
Monastier, Italy w Department of Medicine, Emory University School of Medicine, Atlanta, 
Georgia, USA x Department of Medicine, Walter Reed National Medical Center, Bethesda, MD, 
USA y Duke Clinical Research Institute, Durham, NC, USA
Abstract
Objective—This study sought to determine the correlation between baseline cardiac medications 
and cardiovascular outcomes in patients with obstructive coronary artery disease (CAD) diagnosed 
by coronary computed tomographic angiography (CCTA).
Methods—1637 patients (mean age 64.8 ± 10.2 years, 69.6% male) with obstructive CAD from 
the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational 
Multicenter) registry were followed over the course of three years. Obstructive CAD was defined 
as a >50% stenosis in an epicardial vessel. Medications analyzed included statins, aspirin, beta-
blockers, angiotensin converting enzyme (ACE) inhibitors, and angiotensin receptor blockers 
(ARBs). Using Cox proportional-hazards models, we calculated the hazard ratio (HR) with 95% 
confidence intervals (95% CIs) for incident major adverse cardiovascular events (MACE), defined 
as death, acute coronary syndrome, or myocardial infarction.
Results—At the time of CCTA, 59%, 54%, 40%, and 46% of patients were using statins, aspirin, 
beta-blockers, and ACE inhibitors or ARBs, respectively. Statins were associated with a 43% 
(95% CI = 0.38-0.87, p=0.008) lower adjusted risk of MACE. Following adjustment, aspirin, beta-
blockers, ACE inhibitors and ARBs did not attenuate the risk of MACE. When restricted to 
patients with multivessel obstructive CAD, only statins were associated with lower risk of MACE.
Conclusion—In patients with obstructive CAD by CCTA, the baseline use of statins was 
associated with improved clinical outcomes. Other cardiac medications—including aspirin, beta-
blockers, ACE inhibitors, and ARBs—were not associated with reduced risk of MACE.
Keywords
Coronary Artery Disease; Coronary computed tomographic angiography; major adverse cardiac 
events; medication therapy; statins
INTRODUCTION
Coronary computed tomographic angiography (CCTA) is a noninvasive imaging modality 
that permits accurate detection and exclusion of obstructive coronary artery disease (CAD), 
although the ideal medical management of patients with CCTA-identified obstructive CAD 
remains unclear. For patients without prior known myocardial infarction or coronary 
revascularization, current guidelines advocate the use of statins as a first-line therapy.[1–3] 
Whether intensification of medical therapy with medications such as beta-blockers, 
angiotensin converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) 
is associated with improved cardiovascular outcomes is unknown.[2] In the present 
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prospective multi-site international study, we examined the association between clinical 
outcomes and baseline cardiac medications for patients with newly identified obstructive 
CAD by CCTA.
METHODS
Study population
The CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An 
InteRnational Multicenter) registry is a global, multicenter, observational registry 
comprising clinical, procedural, and follow-up data for 27,125 patients undergoing CCTA 
for clinically indicated reasons. Details concerning the CONFIRM registry's design and 
rationale have been published previously.[4,5] Briefly, inclusion criteria for this analysis 
were patients referred for suspected CAD who were subsequently identified as having at 
least obstructive coronary stenosis, as defined by a >50% luminal stenosis (n=2,807). 
Patients were excluded from this study if they had a prior diagnosis of MI or prior coronary 
revascularization. Medication data were not collected at all CONFIRM sites, and patients 
with incomplete medication data were excluded (n=1,170). Each study site received 
institutional review board approval for all registry procedures, including follow-up 
methodologies.
Clinical data collection
Standardized data collection methods were employed at participating study sites.[4,5] Data 
were systematically collected for each consecutive patient, while applying consistent 
definitions for suspected cardiac symptoms, risk factors, and angiographic CAD extent and 
severity. Patient information was gathered for traditional cardiac risk factors including 
hypertension, diabetes, dyslipidemia, current smoking, and a family history of premature 
CAD. Patients who were treated for hypertension, diabetes, or dyslipidemia, or who 
otherwise had a prior diagnosis for these conditions were categorized as having that risk 
factor. Family history of premature CAD was defined as a primary relative with a diagnosis 
early in life (i.e., mother <65 years of age or father <55 years of age). Chest pain was 
defined and categorized by the interviewing physician as non-anginal, atypical angina, or 
typical angina pectoris.
CCTA Performance and Interpretation
Standardized protocols for image acquisition, as defined by the Society of Cardiovascular 
Computed Tomography, were employed at all participating sites. Specific details of CCTA 
procedures have been defined in detail elsewhere.[4] Each site applied the standard anatomic 
segmental analysis for image interpretation. All segments were coded for the presence and 
severity of coronary stenosis and were scored as normal (0% luminal stenosis), mild-
moderate (1% to 49% luminal stenosis), or obstructive (>50% luminal stenosis). Stenoses 
were judged on a per-patient and per-vessel basis, with the latter based upon stenosis in the 
left main (LM) artery, the left anterior descending (LAD) artery, the left circumflex (LCx) 
artery and the right coronary artery (RCA).
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Study outcome
Patients were followed prospectively over the course of 3 years. The primary outcome 
measure was major adverse cardiovascular events (MACE), which included a combination 
of death from any cause, acute coronary syndrome (ACS), and non-fatal MI that occurred 
during the initial 3 years following CCTA. An ACS was defined as a hospitalization with 
the occurrence of unstable anginal symptoms with electrocardiographic changes. Acute MI 
was further ascertained using biomarker quantification during patients’ hospital stay. 
Ascertainment and adjudication of events in CONFIRM have previously been described.[4] 
All-cause mortality was adjudicated by trained study personnel or by querying of national 
medical databases. Cause of death was not collected in CONFIRM. Other outcomes were 
ascertained by direct interview or telephone contact using a standard script or through 
review of medical records.
Statistical methods
Categorical variables are presented as counts and proportions. Continuous variables are 
presented as means ± SD. Variables were compared using the chi-squared test for 
categorical variables and by Student's unpaired t-test for normally distributed variables, or 
by Wilcoxon's non-parametric test for non-normally distributed variables. Time-to-event 
analyses for the study endpoint were calculated using univariable Cox proportional-hazards 
models reporting hazard ratios (HR) with 95% confidence intervals (95% CIs). Given 
considerable medication heterogeneity, a medication was considered present if the patient 
was taking the medication regardless of concurrent therapies. Multivariable Cox 
proportional hazards models were also constructed with variables based on clinical judgment 
and prior CONFIRM analyses.[5,6]. Variables included baseline demographics, cardiac risk 
factors, individual medications, number of vessels with obstructive disease, and coronary 
revascularization. In multivariable analyses, all variables were adjusted for simultaneously. 
This approach controlled for the effect of baseline differences in the comparator cohorts as 
well as the impact of non-randomized treatment allocation on survival. A two-tailed p-value 
of <0.05 was considered statistically significant. All statistical analyses were conducted 
using SAS version 9.3 (www.sas.com, Cary, NC).
RESULTS
Clinical characteristics of the study population (n=1637) and patients with incomplete 
medication data (n=1170) are listed in Table 1. Overall, the study population had a higher 
burden of risk factors but similar severity of obstructive CAD. In the study population, 
slightly more than half (59%) of the patients were taking statins, 54% aspirin, 40% beta-
blockers, and 46% ACE inhibitors/ARBs. Approximately two thirds (61%) of patients had 
chest pain symptoms. By CCTA, 60% of patients were diagnosed with 1-vessel CAD, 23% 
with 2-vessel CAD, and the remainder with 3-vessel or LM disease. Many of the study 
patients were on multiple medications (Table 2). Overall, 116 (7.1%) of the patients 
experienced the study outcome (43 nonfatal acute coronary syndromes, 7 fatal acute 
coronary syndromes, 66 other deaths).
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Univariable and Multivariable Clinical Predictors of Major Adverse Cardiac Event Risk
As shown in Table 3, the unadjusted risk of MACE was associated with older age, 
hypertension, and increasing severity of CAD. In multivariable analysis, only age and 
increasing severity of CAD remained strong independent predictors of MACE.
Univariable and Multivariable Medication Predictors of Major Adverse Cardiac Event Risk
Aspirin was associated with a reduced unadjusted risk of MACE, whereas the associations 
between statin, beta-blocker and ACE inhibitor use and MACE were not significant (Figure 
1). Yet, in multivariable analyses, statins were predictive of lowering the risk of MACE, 
while aspirin, beta-blockers, and ACE inhibitors were not (Table 3). Similar results were 
found when the analyses were restricted to patients with increased extent and severity of 
CAD (Table 4). The relationship between statins and MACE did not differ materially (HR 
0.43, 95% CI = 0.25-0.75, p=0.003) after omitting patients with subsequent coronary 
revascularization. In a further sensitivity check, only statins remained associated with 
decreased MACE (HR 0.56, 95% CI 0.35-0.88, p=0.01) in the cohort inclusive of patients 
with incomplete medication data.
Analysis of Differing Medication Regimens
In exploratory analyses, no medication combination was associated with additional 
improvements in survival compared to statins alone. Similarly, when compared to the use of 
statins alone, the use of all four classes of medication was not associated was significant 
additional improvement in survival (Figure 2).
DISCUSSION
In this large, global, multicenter registry of patients with obstructive CAD diagnosed by 
CCTA, baseline statin use was consistently associated with a reduction in the risk of MACE 
across 3 years of follow-up. Other cardiac medications (aspirin, beta blockers, ACE 
inhibitors and ARBs) were not significantly associated with reduced MACE. These findings 
suggest that patients with obstructive CAD diagnosed by CCTA derive the largest benefit 
from a medication regimen that includes statins.
Prior studies of statins for both primary and secondary prevention in patients with 
established CAD have reported considerable improvements in adverse outcomes.[7–9] A 
large meta-analysis of statin therapy in patients at low vascular risk demonstrated a 20% risk 
reduction in vascular events for each 1.0mmol/L (40mg/dL) decrement in LDL. Statins were 
associated with reductions in major coronary events, cardiac revascularization, stroke, 
cardiac mortality and all-cause mortality even in patients at low vascular risk.[7] In 
secondary prevention patients (most of whom had prior MI or revascularization), statin use 
was associated with even greater declines in all-cause mortality and major vascular events.
[9] To date, few studies have examined the precise benefit of statins in patients with 
obstructive CAD diagnosed by CCTA. One recent retrospective study of patients with 
atypical chest pain who were found to have non-obstructive CAD by CCTA failed to 
observe a significant clinical improvement in patients subsequently initiated on statins.[10] 
However, this study used a propensity score matching approach and was retrospective. 
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Conversely, the current analysis was restricted to patients with obstructive CAD diagnosed 
by CCTA, which is a cohort at higher risk of adverse events.[5] Our present findings suggest 
that such patients may derive greater absolute benefit from early and aggressive statin 
initiation than patients with lesser amounts of atherosclerosis. This notion is additive to the 
prior literature in that until recently, many patients with suspected CAD in statin trials did 
not have direct visualization of their coronary anatomy. Further studies regarding the 
interplay of anatomic CAD, ischemia, and statins in patients with CAD but without prior MI 
thus appear warranted. In the meanwhile, our findings lend further support to current 
recommendations that patients with obstructive CAD by CCTA should be treated with 
statins similar to other patients with chronic stable ischemic heart disease [1,2].
Previous meta-analyses exploring the effects of aspirin in secondary prevention have 
reported a beneficial reduction in the risk of fatal and non-fatal events.[11,12] Conversely, 
the role of aspirin in primary prevention is much less clear, even in high-risk groups such as 
diabetics, largely because of increased bleeding rates.[12–14] In this study, while the use of 
aspirin was associated with a decline in the risk of MACE, the relationship marginally 
attenuated to non-significance after adjusting for numerous covariates. Had there been a 
longer duration of follow-up with sufficient sample size, it is feasible this trend may have 
reached statistical significance. In this light, future studies regarding the use of aspirin in 
patients with obstructive CAD as diagnosed by CCTA are needed.
Of the other cardiac medications examined in this study, neither beta-blockers nor ACE 
inhibitors were related to the risk of MACE. While beta blockers improve symptoms of 
stable angina, no studies to date have demonstrated improved MACE outcomes from beta 
blocker use in patients with stable CAD without prior MI. In such patients, beta blockers are 
therefore indicated only for symptomatic relief under current guidelines. [2,3] Among 
patients with stable CAD and preserved left ventricular function, ACE inhibitors have been 
associated with a small reduction in mortality, MI, and revascularization.[15–17] Guidelines 
therefore state that ACE inhibitors/ARBs may be considered a useful adjunct in patients 
with stable CAD and other vascular risk factors.[2,3] Additional research is clearly 
warranted to determine the benefits, if any, of these medication classes among patients with 
obstructive CAD as diagnosed by CCTA.
Several limitations need to be emphasized. The patients involved in this study reflected only 
a small sample of the overall patients enrolled in the CONFIRM registry. Hence, the number 
of clinical endpoints was relatively small. The CONFIRM registry did not collect cause of 
death, and as such, not all deaths may be cardiovascular or related to the CCTA findings. 
Furthermore, other relevant outcomes such as stroke were not ascertained in CONFIRM. For 
myocardial infarction, there is a possible limitation of events being adjudicated by phone or 
medical review. Still, it should be noted that this is the largest prospective registry of 
consecutively enrolled CCTA patients for whom outcome data are available. During the data 
collection phase of this study, medication dosage, name and prior duration of therapy were 
not collected, nor was information regarding any subsequent change in medication, risk 
factor modification, or lifestyle changes following the results of patients’ CCTA. Further 
studies should clarify the effect of CCTA on subsequent medication management. The 
present study had insufficient data concerning left ventricular function or history of 
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congestive heart failure, which may limit the interpretation of the findings regarding the 
impact of beta-blockers and ACE inhibitors.
Growing numbers of patients are frequently diagnosed with obstructive CAD by novel 
imaging modalities such as CCTA. We have previously reported that these patients are at 
increased risk of mortality and adverse cardiovascular outcomes.[5,18] However, there are 
few data guiding the management of such patients. Many contemporary patients may not 
have met eligibility criteria for older secondary prevention trials, yet it is unclear whether 
they should be considered similar to primary prevention cohorts with cardiovascular risk 
factors alone. The current study suggests a beneficial association between early statin 
initiation and reduced clinical events in patients with obstructive CAD diagnosed by CCTA. 
The baseline use of other cardiac medications including aspirin, beta blockers, ACE 
inhibitors or ARBs were not associated with reductions in MACE risk, but these findings 
may be limited owing to insufficient data regarding medication changes subsequent to the 
CCTA. While further research is clearly needed to guide the treatment of patients with 
obstructive CAD diagnosed by CCTA, at the minimum, our findings support efforts to 
increase the use of statins in such patients.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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CCTA Coronary computed tomographic angiography
CAD coronary artery disease
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LM Left Main
LAD left anterior descending
LcX left circumflex
RCA right coronary artery
MACE major adverse cardiac events
ACS Acute coronary syndrome
HR hazard ratio
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Highlights
• We analyzed medication use of patients with obstructive CAD diagnosed by 
CCTA
• Statins were significantly associated with lower risk of MACE
• Secondary prevention medications were not associated with reduced risk of 
MACE
• Findings were similar in patients with multivessel CAD
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Figure 1. Unadjusted 3-Year Survival by the Use of Selected Medications Survival curves for 
statins, aspirin, beta-blockers, ACE inhibitors/ARBs
Presence of medication may also include other medications
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Figure 2. 
Unadjusted Survival by Primary versus Secondary Medication Regimen
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Table 1
Study demographics
Complete Med Data (n=1637) Incomplete Med Data (n=1170) p-value
Age, mean ± SD 64.8±10.2 61.7 ± 10.5 <0.001
Male, n (%) 1139 (69.6) 762 (65.2) 0.014
Cardiovascular risk factors, n (%)
    Current smoker 388 (23.8) 196 (16.9) <0.001
    Diabetes 390 (23.9) 234 (20.2) 0.02
    Family history of premature CAD 552 (33.8) 1019 (37.1) <0.001
    Hyperlipidemia 1142 (70.1) 754 (65.3) 0.007
    Hypertension 1064 (65.2) 709 (62.0) 0.08
Chest Pain, n (%) <0.001
    Typical 327 (20.7) 158 (14.1)
    Atypical 502 (31.8) 395 (35.3)
    Non-cardiac 138 (8.8) 110 (9.8)
    Asymptomatic 610 (38.7) 457 (40.8)
Dyspnea, n (%) 250 (16.6) 425 (46.1) <0.001
Medication, n (%)
    Statins 970 (59.3) na
    Aspirin 883 (53.9) na
    Beta-blockers 651 (39.8) na
    ACE inhibitors/ARBs 747 (45.6) na
    Other* 559 (34.2) na
CAD Severity, n (%) 0.74
    1-vessel 987 (60.3) 702 (60.1)
    2-vessel 382 (23.3) 285 (24.4)
    3-vessel 268 (16.4) 182 (15.6)
Any coronary revascularization 403 (24.6) 368 (31.5) <0.001
Early coronary revascularization (<90 days) 278 (17.0) 295 (25.2) <0.001
*
Includes nitrates, calcium channel blockers, and non-statin lipid lowering medications
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Table 2
Baseline Characteristics Stratified by Medication
Statin (n=970) Aspirin (n=833) Beta Blocker (n=651) Ace Inhibitor/ARB (n=747)
Age, mean ± SD 64.9 ± 9.5 64.4 ± 10.1 65.1 ± 9.9 65.2 ± 9.7
Male, n (%) 677 (69.8) 610 (69.1) 424 (65.1) 503 (67.3)
Cardiovascular risk factors, n (%)
    Current smoker 228 (23.6) 167 (19.0) 130 (20.2) 150 (20.2)
    Diabetes 259 (26.8) 242 (27.6) 176 (27.3) 215 (29.0)
    Family history of premature CAD 351 (36.3) 246 (27.9) 176 (27.1) 224 (30.1)
    Hyperlipidemia 837 (86.7) 627 (71.5) 462 (71.4) 503 (67.9)
    Hypertension 644 (66.6) 567 (64.7) 458 (70.9) 555 (74.6)
Chest Pain, n (%)
    Typical 354 (38.2) 347 (41.3) 251 (40.7) 310 (43.0)
    Atypical 281 (30.3) 265 (31.6) 197 (31.9) 232 (32.2)
    Non-cardiac 81 (8.7) 35 (4.2) 38 (6.2) 44 (6.1)
    Asymptomatic 212 (22.8) 192 (23.0) 131 (21.2) 135 (18.7)
Dyspnea, n (%) 132 (14.7) 112 (14.0) 90 (15.3) 118 (18.0)
Medication, n (%)
    Statin 970 (100) 586 (66.4) 427 (65.6) 460 (61.6)
    ASA 586 (60.4) 883 (100) 489 (75.1) 490 (65.6)
    Beta blocker 427 (44.0) 489 (55.4) 651 (100) 399 (53.4)
    ACEi/ARB 460 (47.4) 490 (55.5) 399 (61.3) 747 (100)
    Other 372 (38.4) 444 (50.3) 303 (46.5) 293 (39.2)
CAD Severity, n (%)
    1-vessel 547 (56.4) 544 (61.6) 382 (58.7) 460 (61.6)
    2-vessel 241 (24.9) 206 (23.3) 171 (26.3) 176 (23.6)
    3-vessel 182 (18.8) 133 (15.1) 98 (15.1) 111 (14.9)
Any coronary revascularization 291 (30.0) 192 (21.7) 166 (25.5) 206 (27.6)
Early coronary revascularization (<90 days) 181 (18.7) 109 (12.3) 108 (16.6) 144 (19.2)
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Table 3
Clinical characteristics associated with MACE for patients with obstructive CAD
Univariable HR (95% CI) p-value Multivariable HR (95% CI) p-value
Age 1.06 (1.04-1.08) <0.001 1.06 (1.04-1.08) <0.001
Male 1.00 (0.67-1.49) 1.00 1.15 (0.76-1.74) 0.51
Diabetes 1.12 (0.74-1.69) 0.60 1.12 (0.74-1.70) 0.59
Family history of premature CAD 1.26 (0.86-1.84) 0.23 1.24 (0.83-1.83) 0.29
Hyperlipidemia 1.06 (0.71-1.59) 0.78 1.46 (0.92-2.30) 0.11
Hypertension 1.93 (1.25-2.96) 0.003 1.50 (0.96-2.34) 0.07
Current smoker 1.40 (0.94-2.08) 0.10 1.45 (0.96-2.19) 0.08
Medication
    Statins 0.74 (0.51-1.06) 0.10 0.57 (0.38-0.87) 0.008
    Aspirin 0.65 (0.45-0.93) 0.02 0.74 (0.49-1.12) 0.16
    Beta-blockers 0.95 (0.66-1.38) 0.80 1.05 (0.70-1.59) 0.80
    ACE inhibitors 1.27 (0.88-1.83) 0.20 1.38 (0.91-2.08) 0.13
CAD Severity
    1-vessel 1.00 (Reference)
    2-vessel 2.04 (1.33-3.14) 0.001 1.86 (1.20-2.88) 0.006
    3-vessel/left main 2.52 (1.61-3.95) <0.001 1.97 (1.23-3.16) 0.005
Early coronary revascularization(<90days) 1.97 (1.31-2.95) 0.001 1.64 (1.08-2.48) 0.02
*Multivariable HR adjusted for age, sex, clinical risk factors, medication, CAD severity, and early coronary revascularization. CAD indicates 
coronary artery disease; HR, hazard ratio; CI, confidence interval.
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Table 4
Clinical Characteristics Associated with MACE for Patients with More Extensive CAD
2v/3v/LM CAD (n=650) 3v/LM CAD (n=268)
Variable Multivariable HR (95% CI) p-value Multivariable HR (95% CI) p-value
Age 1.03 (1.00-1.06) 0.03 1.05 (1.01-1.10) 0.03
Male 0.91 (0.52-1.58) 0.74 0.81 (0.36-1.83) 0.61
Diabetes 1.46 (0.86-2.48) 0.16 2.20 (1.04-4.64) 0.04
Family history of premature CAD 1.46 (0.88-2.44) 0.14 1.82 (0.84-3.91) 0.13
Hyperlipidemia 1.35 (0.73-2.49) 0.34 2.40 (0.85-6.77) 0.10
Hypertension 1.17 (0.66-2.08) 0.60 0.61 (0.26-1.42) 0.25
Current smoker 1.16 (0.68-2.00) 0.58 1.37 (0.61-3.09) 0.45
Medications
    Statins 0.44 (0.25-0.77) 0.004 0.30 (0.12-0.74) 0.009
    Aspirin 0.74 (0.42-1.28) 0.28 0.83 (0.35-1.93) 0.66
    Beta-blockers 1.05 (0.60-1.82) 0.87 0.50 (0.20-1.25) 0.14
    ACE inhibitors 1.56 (0.89-2.74) 0.12 1.48 (0.58-3.79) 0.41
Early coronary revascularization(<90days) 1.56 (0.92-2.64) 0.10 1.87 (0.88-3.96) 0.11
*Multivariable HR adjusted for age, sex, clinical risk factors, medications, CAD severity, and early coronary revascularization. 2v indicates two 
vessel, 3v three vessel, LM left main, CAD coronary artery disease; HR, hazard ratio; CI, confidence interval.
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